Osimertinib
Epithelioid Hemangioendothelioma (EHE)
Ikena OncologySmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Epithelioid Hemangioendothelioma (EHE) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Gdc-0449 National Cancer Institute (NCI) | Phase 1/2 | CCC |
Benzenesulfonamide, N-methyl-3-(1-methyl-1H-imidazol-4-yl)-4-[[[4-(trifluoromethyl)phenyl]methyl]amino]- Ikena Oncology | Phase 1 | CC |
rg4733 National Cancer Institute (NCI) | Phase 1/2 | CC |
bgc515 BridGene Biosciences Inc. | Phase 1 | NR |
Same molecule, other indications
Osimertinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →